KING OF PRUSSIA, Pa., Feb. 25 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that Dov A.
Goldstein, M.D., Executive Vice President and CFO will present at the Wells
Fargo Securities Healthcare Conference at 1:30 p.m. Eastern Standard Time on
Tuesday, March 1, 2005 at the St. Regis Hotel in New York City.
To access the live audio broadcast or the subsequent archived recording
log on to http://www.vicuron.com and click on the investor relations section.
Please connect to the website several minutes prior to the start of the
webcast to ensure adequate time for any software download that may be
necessary. The live broadcast will be archived for 30 days.
About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital medicine for
seriously ill patients. The company has two New Drug Applications pending
with the U.S. Food and Drug Administration for its lead products, dalbavancin,
a novel intravenous antibiotic for the treatment of serious Gram-positive
infections, and anidulafungin, a novel antifungal agent. Vicuron's versatile
research engine integrates industry-leading expertise in functional genomics,
natural products discovery, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel and
next-generation compounds, many of which are in the later stages of
preclinical development. In addition, the company has research and
development collaborations with leading pharmaceutical companies, such as
Novartis and Pfizer.
Forward-Looking Statements
The presentation contains forward-looking statements that predict or
describe future events or trends. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are beyond
Vicuron's control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that clinical trials
and the results thereof might be delayed or unsuccessful, that the timing of
the filing of any new drug application or any amendment to a new drug
application might be delayed, that clinical trials might indicate that a
product candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be taken
before it will make any decision, that any filed new drug application may not
be approved by the FDA, that ongoing proprietary and collaborative research
might not occur or yield useful results, that the pipeline may not yield a new
clinical candidate or a commercial product, that a third party may not be
willing to license Vicuron's product candidates on terms acceptable to it or
at all, that competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively, that a sales
force may not be developed as contemplated and that one or more of Vicuron's
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a
fuller description of these and many other risks to which Vicuron is subject.
Because of those risks, Vicuron's actual results, performance or achievements
may differ materially from the results, performance or achievements
contemplated by its forward-looking statement. The information set forth in
the presentation represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the forward-looking
matters discussed in the presentation.
SOURCE Vicuron Pharmaceuticals Inc.
 back to top
Related links:
http://www.vicuron.com
CONTACT:
Dov A. Goldstein, M.D. of Vicuron
Pharmaceuticals Inc., +1-610-205-2312, dgoldstein@vicuron.com; or
E. Blair Schoeb of WeissComm Partners, +1-212-923-6737,
blair@weisscommpartners.com; or Aline Schimmel of Burns McClellan
Inc., +1-212-213-0006, aschimmel@burnsmc.com; both for Vicuron
Pharmaceuticals Inc.
|
